NCT02859025

Brief Summary

Our aim was to combine regenerative techniques with bone grafting in human models to increase predictability and survival of reconstructed tissue. The MSCs in this study were derived from an intra oral fat source (BFP) and were cultured over natural bovine bone mineral granules and delivered within the lateral ramus cortical bone plate (LRCP)to treat human alveolar cleft defects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jan 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 30, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 8, 2016

Completed
Last Updated

August 8, 2016

Status Verified

August 1, 2016

Enrollment Period

1 year

First QC Date

July 30, 2016

Last Update Submit

August 3, 2016

Conditions

Keywords

Alveolar cleftOsteoplastyTissue engineeringStem cellsRegenerative medicineBoneLateral ramus

Outcome Measures

Primary Outcomes (1)

  • change in bone volume

    1-mm coronal sections of the treated region were taken before and after surgery, and new bone formation was assessed by CBCT.

    before the surgery and 6 months after the surgery

Study Arms (3)

A:Iiac

ACTIVE COMPARATOR

Treated with anterior iliac crest spongy bone to fill defects, followed by coverage with collagen membrane.

Biological: anterior iliac crest graft

B:MSCs+LRCP

EXPERIMENTAL

Treated with lateral ramus cortical bone plate (LRCP) to create a protected healing space by fixing it to adjacent walls of the cleft defect. BFPScs were loaded on NBBM and delivered to the defect

Biological: lateral ramus cortical bone+BFPSC+NBBM

C:MSCs+liac

EXPERIMENTAL

Treated with anterior iliac crest spongy bone as in Group 1, but BFP-derived mesenchymal stem cells (MSCs ) cultured over NBBM were put over the spongy bone and covered with a collagen membrane.

Biological: anterior iliac crest graft+BFPSC+NBBM

Interventions

Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.

A:Iiac

ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.

B:MSCs+LRCP

Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.

C:MSCs+liac

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Unilateral congenital cleft lip and palate
  • Previous presurgical orthodontic treatment

You may not qualify if:

  • History of malignancy
  • History of radiation
  • History of chemotherapy
  • Pregnancy
  • Systemic diseases contradicting dental and surgical treatments
  • Conditions or drugs affecting bone remodeling or bone metabolism and connective tissue
  • Allergy to collagen

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School of Dentristry at Shahid Beheshti University of Medical Sciences

Tehran, Tehran Province, 19839, Iran

Location

Related Publications (1)

  • Khojasteh A, Kheiri L, Behnia H, Tehranchi A, Nazeman P, Nadjmi N, Soleimani M. Lateral Ramus Cortical Bone Plate in Alveolar Cleft Osteoplasty with Concomitant Use of Buccal Fat Pad Derived Cells and Autogenous Bone: Phase I Clinical Trial. Biomed Res Int. 2017;2017:6560234. doi: 10.1155/2017/6560234. Epub 2017 Dec 12.

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

July 30, 2016

First Posted

August 8, 2016

Study Start

January 1, 2015

Primary Completion

January 1, 2016

Study Completion

February 1, 2016

Last Updated

August 8, 2016

Record last verified: 2016-08

Locations